Table 1.

Antiproliferative effects and HNTCs (fixed) of the different anticancer agents in HUVECs after a 1-hour drug exposure period followed by a 96-hour drug-free period

DrugIC50 (nmol/L ± SD)HNTC* (nmol/L)Endothelial cell growth at HNTC (% ± SD)
Cisplatin58,500 ± 5,30010,00096.9 ± 14.6
Doxorubicin1,500 ± 1,40010094.9 ± 7.5
Docetaxel21.3 ± 2.11098.4 ± 13.1
Epothilone B1.9 ± 1.91100.1 ± 6.4
Vinblastine71.5 ± 4.91084.5 ± 6.0
  • * Concentration of the drug not yet interfering with proliferation.

  • Endothelial cell growth at HNTC expressed as a percentage of control cell growth.